Sodium Chloride Or Plasmalyte Evaluation for patients with DiabeticKetoAcidosis (SCOPE-DKA)

Phase 2

Completed

• Conditions: Diabetic ketoacidosis; Metabolic and Endocrine - Diabetes; Metabolic and Endocrine - Metabolic disorders

• Registration Number: ACTRN12618001622291
• Lead Sponsor: Trial Management Committee

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2018-10-02
• Study Completion: 2021-01-31
• Last Update Posted: 15 August 2022

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 93

Inclusion Criteria

Patients greater than or equal to 16 years of age, admitted to the emergency department at participating sites with a diagnosis of diabetic ketoacidosis, which was defined as:
•Blood glucose level greater than 14 mmol/L
AND
•pH less than 7.25 OR serum bicarbonate less than 15 mmol/L
AND
•ICU admission required in the judgement of the treating clinician

Exclusion Criteria

•Age less than 16
•Serum potassium greater than 6.5 mmol/L prior to randomisation
•Patients with hyperosmotic hyperglycaemic, non-ketotic syndrome
•Patients who have previously been included in this trial

Study & Design

• Study Type: Interventional
• Study Design: Not specified